Physician profile
Amanda L Daniel
NPI 1861668907
$19,769.29
in general payments reported to CMS, 2019-2025
55 companies · $2,911 in 2025
The $2,911 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,779 · 2020: $2,300 · 2021: $2,651 · 2022: $2,658 · 2023: $3,299 · 2024: $3,171 · 2025: $2,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,381.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,945.20 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $2,669.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $2,367.78 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $1,693.92 | 2019-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $774.96 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $762.90 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $748.49 | 2019-2025 | Synthroid |
| Insulet Corporation | $675.03 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $592.85 | 2019-2024 | |
| Cequr Corporation | $457.00 | 2023-2025 | Cequr Simplicity |
| Mannkind Corporation | $428.13 | 2019-2024 | |
| Ibsa Pharma INC. | $407.60 | 2020-2025 | Tirosint, Licart, Tirosint |
| Beta Bionics, INC. | $387.22 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $385.21 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Ascensia Diabetes Care US INC. | $358.21 | 2022-2023 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.